Nykredit A S Acquires New Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Nykredit A/S acquired 465,263 Bristol Myers Squibb shares in the second quarter, valued at approximately $26.8 million. Institutional investors collectively own 76.41% of BMY.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $66.72 price target. Bristol Myers Squibb recently exceeded quarterly earnings and revenue expectations, reporting $2.04 EPS and $12.97 billion in revenue.
• BMY announced a quarterly dividend of $0.63 per share, equivalent to $2.52 annually and an approximately 4% yield based on the reported share price. The stock opened at $62.92, while an insider recently sold 500 shares.

Nykredit A S acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 465,263 shares of the biopharmaceutical company's stock, valued at approximately $26,808,000.

Several other large investors have also recently bought and sold shares of BMY. KCM Investment Advisors LLC boosted its position in shares of Bristol Myers Squibb by 0.8% during the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company's stock valued at $1,126,000 after purchasing an additional 174 shares in the last quarter. Sandy Cove Advisors LLC grew its position in Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company's stock worth $227,000 after buying an additional 176 shares during the last quarter. Investment Research Partners LLC increased its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company's stock valued at $708,000 after buying an additional 179 shares in the last quarter. REAP Financial Group LLC lifted its position in shares of Bristol Myers Squibb by 26.1% during the 4th quarter. REAP Financial Group LLC now owns 879 shares of the biopharmaceutical company's stock valued at $47,000 after acquiring an additional 182 shares during the last quarter. Finally, Key Financial Inc grew its holdings in shares of Bristol Myers Squibb by 2.4% in the 1st quarter. Key Financial Inc now owns 7,939 shares of the biopharmaceutical company's stock worth $482,000 after acquiring an additional 183 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.05% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BMY shares. Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. Truist Financial restated a "buy" rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. HSBC reissued a "hold" rating and set a $65.00 price target (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. Piper Sandler restated an "overweight" rating and set a $82.00 price objective (up from $75.00) on shares of Bristol Myers Squibb in a research report on Wednesday. Finally, Royal Bank Of Canada increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $66.72.

Bristol Myers Squibb Stock Up 0.1%

BMY opened at $62.92 on Friday. The company has a market capitalization of $128.53 billion, a PE ratio of 13.86, a price-to-earnings-growth ratio of 0.30 and a beta of 0.23. The business has a 50-day moving average of $64.20 and a 200-day moving average of $60.14. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 earnings per share. The firm's revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 55.51%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Sotyktu data: Two-year results showed durable efficacy and consistent safety in adults with psoriatic arthritis, supporting the drug’s potential as a growth contributor and helping drive recent investor interest. Bristol Myers Squibb Presents Sotyktu Data
• Positive Sentiment: Dividend remains attractive: BMY reaffirmed a quarterly dividend of $0.63 per share, payable November 2, implying an annualized yield of roughly 4% based on the provided share price. The stock’s ex-dividend date is October 2. Bristol Myers Squibb Dividend and Sotyktu Update
• Positive Sentiment: Analyst and estimate support: Piper Sandler initiated or reiterated a Buy view, while an analyst raised the third-quarter EPS estimate. These actions suggest improving confidence in near-term earnings. Piper Sandler Buy Rating
• Positive Sentiment: Value appeal: BMY trades at a relatively modest valuation, with a provided P/E ratio of about 13.9 and a PEG ratio of 0.30. Value-focused coverage is likely reinforcing interest in the shares. Should Value Investors Buy Bristol Myers Squibb Stock?
• Neutral Sentiment: Bristol Myers Squibb will report third-quarter 2026 results on October 29, giving investors a significant upcoming catalyst for assessing earnings momentum and guidance. Bristol Myers Squibb Third-Quarter Results Date
• Neutral Sentiment: The company is funding lung-cancer screening research in India beyond smoking-related risk factors. The initiative may support BMY’s public-health profile but is unlikely to materially affect near-term earnings. Bristol Myers Squibb Funds India Lung Cancer Research
• Negative Sentiment: Investors remain concerned that BMY is navigating revenue declines and legal uncertainty, making AbbVie appear more attractive to some healthcare investors despite BMY’s valuation and dividend support. AbbVie vs. Bristol Myers Squibb

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.